tiprankstipranks
Cencora Reports Strong Revenue and EPS Growth in 2024
Company Announcements

Cencora Reports Strong Revenue and EPS Growth in 2024

Cencora ( (COR) ) just unveiled an update.

Don't Miss our Black Friday Offers:

Cencora, Inc. reported significant growth in its fiscal 2024 results, boasting a 14.7% increase in fourth-quarter revenue to $79.1 billion and a 12.1% rise for the year to $294.0 billion. Despite a drop in GAAP diluted EPS to $0.02 in the fourth quarter, adjusted EPS saw a robust 16.8% rise to $3.34. The company enhanced its strategic pharmaceutical distribution capabilities and expanded its specialty services with the acquisition of Retina Consultants of America. Cencora remains committed to growth and long-term value creation for stakeholders.

See more data about COR stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCencora Expands Specialty Healthcare with RCA Acquisition
TheFlyCencora price target raised to $285 from $275 at UBS
TheFlyCencora price target raised to $292 from $287 at Baird
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App